23andMe Investor Presentation Deck

Phase 1 Study Design for GSK6097608 (GSK'608): A High Affinity Monoclonal Antibody Against CD96 Study Design Phase 1 Study population: * Locally advanced, recurrent, or metastatic solid tumors Nonrandomized * Progressed after, intolerant of, or inappropriate for standard therapy Open label Escalating doses of GSK6097608 Q3W 0 000 Sequential assignment Arm A (GSK6097608) Escalating doses of GSK6097608 Q3W + fixed dose of dostarlimab Q3W Multicenter RP2D determined Enrollment in arm B begins once a dose of GSK6097608 from arm A has been identified based on safety and PK/PD data Enrollment in PK/PD cohort Arm B (GSK6097608 + dostarlimab) RP2D determined Enrollment in PK/PD cohort https://www.clinical trials.gov/ct2/show/NCT04446351 ADA, anti-drug antibodies; AEs, adverse events; ORR, objective response rate; PK, pharmacokinetics; PK/PD, pharmacokinetics/pharmacodynamics; Q3W, every 3 weeks; RP2D, recommended Phase 2 dose Study Endpoints Primary Secondary - Dose limiting toxicities *Adverse events * ORR per RECIST 1.1 - ADAs against GSK6097608 and dostarlimab - PK parameters of GSK6097608 and dostarlimab Strategic Collaboration with gsk Current Status The study is currently open and recruiting. . Serious adverse events . Clinically important changes in laboratory parameters, electrocardiograms, and vital signs • Dose reductions or delay • Withdrawal due to AES Commenced in 2020; data expected 2022 Copyright © 2022 23and Me, Inc. OPEN 23andMe 41

View entire presentation